ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 2152

A Prospective Randomized Trial of Stem Cell Enriched Autologous Lipotransfer for Orofacial Fibrosis in Systemic Sclerosis (Sys-Stem)

Christopher Denton1, Benjamin Langridge2, Laura Awad2, Rumana Omar2, Martin Wiegand2, Rachel Ochiel2, Lynn Steblecki2, Esther Hansen2 and Peter Butler3

Affiliations: 1University College London, UK, London, United Kingdom, 2Royal Free Hospital, UK, London, United Kingdom, 3University College London, London, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: clinical trial, Fibrosing syndromes, surgery, Systemic sclerosis

Session Information

Date: Tuesday, November 10, 2026

Title: (2152-2163) Systemic Sclerosis & Related Disorders - Treatment Poster C

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Orofacial complications cause major morbidity in systemic sclerosis (SSc) affecting appearance, mouth opening, saliva production alongside significant impact on psychological wellbeing.  Previous uncontrolled studies suggest benefit from autologous lipotransfer with improvement in symptoms and appearance.  We report the results of the first prospective randomized clinical trial comparing facial lipotransfer with routine clinical care.

Methods: This was a prospective randomized feasibility study comparing lipotransfer and “treatment as usual” (TAU) with change in Mouth Handicap in Systemic Sclerosis scale (MHISS) at 6 months as primary endpoint, using a linear regression model accounting for baseline MHISS score. Secondary endpoints included recruitment rate and attrition, willingness to be randomized, mouth opening, stimulated salivary flow rate, Derriford Appearance Scale (DAS24), Brief Fear of Negative Evaluation Scale (BFNE) and Hospital Anxiety and Depression Scale (HADS).

Results: Seventy-seven patients with SSc were approached and 50 consented (consent rate of 63%, 95% CI: [52.6%,73.9%]). Of these, 49 passed eligibility screening. A total of 41 completed 6-month follow-up, including 20 in the intervention arm and 21 in the control arm (TAU).  In the intervention group median (IQR) age was 47.5 years (41, 55), 11 (46%) had diffuse cutaneous (dc) SSc, and 10 taking immunosuppressant treatment (IST).  In the control arm mean age was 54.5 years (46, 60.5), 13 (52%) had dcSSc and 17 (71%) were on IST.   Treatment effect of the active intervention (lipotransfer) was statistically significant for the MHISS primary endpoint of MHISS at 6 months (see Figure 1) with estimate -5.04 (CI -8.74 to -1.34; p= 0.011).  Ten (4 control, 6 intervention) observations were omitted due to missing data.  Secondary endpoint analysis showed numerical improvement favoring lipotransfer for MHISS at 3 months, mouth opening distance, stimulated salivary flow and improvement in psychological functioning (DAS24, BFNE and HADS) at 6 months (see Table 1).

Conclusion: Our findings confirm a significant improvement in MHISS after stem cell enriched autologous lipotransfer to treat orofacial manifestations of SSc. Improvement favoring stem cell enriched autologous lipotransfer was found in patient mouth opening and psychological outcomes at 6 months following treatment. Current incorporation of this surgical intervention into routine care is supported and further studies to assess optimal delivery and biological mechanism should be undertaken. Understanding the underlying biological mechanism may lead to a new antifibrotic therapy.

Supporting image 1Figure 1 Primary clinical outcome of MHISS over 6 months

Supporting image 2Table 1 Sys-Stem trial secondary endpoint data


Disclosures: C. Denton: Argenx, 12,, Bayer, 12,, Boehringer Ingelheim, 12,, Bristol Myers Squibb, 12,, Cabaletta, 12,, Calluna, 12,, Certa, 12,, CSL Behring, 12,, GlaxoSmithKline, 12,, Jannsen, 12,, Lilly, 12,, Novartis, 12,, Quell, 12,, Roche, 12,; B. Langridge: None; L. Awad: None; R. Omar: None; M. Wiegand: None; R. Ochiel: None; L. Steblecki: None; E. Hansen: None; P. Butler: None.

To cite this abstract in AMA style:

Denton C, Langridge B, Awad L, Omar R, Wiegand M, Ochiel R, Steblecki L, Hansen E, Butler P. A Prospective Randomized Trial of Stem Cell Enriched Autologous Lipotransfer for Orofacial Fibrosis in Systemic Sclerosis (Sys-Stem) [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/a-prospective-randomized-trial-of-stem-cell-enriched-autologous-lipotransfer-for-orofacial-fibrosis-in-systemic-sclerosis-sys-stem/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-prospective-randomized-trial-of-stem-cell-enriched-autologous-lipotransfer-for-orofacial-fibrosis-in-systemic-sclerosis-sys-stem/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology